Puma Biotechnology | PBYI - Current Assets

Stock Price
6.62
Daily Change
0.01 0.12%
Monthly
5.38%
Yearly
137.20%
Q1 Forecast
5.65

Puma Biotechnology reported $143.58M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 1.03B 13.64M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Exelixis USD 1.44B 41.03M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Moderna USD 6.6B 427M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Takeda JPY 3.12T 195.82B Dec/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vanda Pharmaceuticals USD 367.5M 27.42M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025